论文部分内容阅读
目的:分析雷贝拉唑与奥美拉唑、兰索拉唑、埃索美拉唑对胃食管反流的诊断价值。方法:选取2016年4月至2017年3月中山市博爱医院100例具有胃食管反流症状的患者,依据入院治疗的先后顺序分为雷贝组、奥美组、兰索组以及埃索美组,每组患者的例数分别为25例,其用药分别为雷贝拉唑、奥美拉唑、兰索拉唑以及埃索美拉唑,对用药后3 d以及7 d的症状积分改变程度进行记录,依据积分下降程度进行临床诊断。结果:雷贝组非胃食管反流病和胃食管反流病治疗7 d后症状积分下降值比较,差异具有统计学意义(P<0.05),奥美组、兰索组以及埃索美组治疗7 d后症状积分下降值比较,差异均无统计学意义(P>0.05),并且患者用药后并无出现严重不良反应。结论:雷贝拉唑作为对胃食管反流患者进行诊断的一种质子泵抑制剂(PPI),和奥美拉唑、兰索拉唑、埃索美拉唑相比诊断价值良好。
Objective: To analyze the diagnostic value of rabeprazole and omeprazole, lansoprazole and esomeprazole on gastroesophageal reflux disease. Methods: From April 2016 to March 2017, 100 patients with gastroesophageal reflux symptoms in Pok Oi Hospital of Zhongshan were enrolled and divided into three groups: Rebebea, Ogilvy, Lansoprazole, Group, the number of patients in each group were 25 cases, respectively, the drugs were rabeprazole, omeprazole, lansoprazole and esomeprazole, 3 d and 7 d after treatment symptoms change The degree of record, according to the degree of decline in clinical diagnosis. Results: There was significant difference in the scores of symptom scores after 7 days of treatment for non-gastroesophageal reflux disease and gastroesophageal reflux disease among the Ogilvy group, Lansoprazole group and esomeprazole group (P <0.05) There was no significant difference (P> 0.05) in the symptom score after 7 days of treatment, and there was no serious adverse reaction after treatment. Conclusions: Rabeprazole is a good proton pump inhibitor (PPI) for diagnosing gastroesophageal reflux disease and has good diagnostic value compared with omeprazole, lansoprazole and esomeprazole.